This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00112/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00112/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00112/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/sukl/drug/
n21http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00112/identifier/drugbank/

Statements

Subject Item
n2:DB00112
rdf:type
n3:Drug
n3:description
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
n3:dosage
n22:271B460F-363D-11E5-9242-09173F13E4C5 n22:271B4610-363D-11E5-9242-09173F13E4C5 n22:271B4611-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Velcheti V, Viswanathan A, Govindan R: The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol. 2006 Jun;1(5):501. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17409907 # IMGT "Link":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1BJ1 # Lexicomp. Bevacizumab. N.p., 2014. Web. 11 Nov. 2014. #Bevacizumab. In DynaMed [database online]. EBSCO Information Services. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated August 18, 2014. Accessed October 1, 2014. #Hoffmann-La Roche Limited. Bevacizumab. Mississauga, Ontario: N.p., 2014.
n3:group
investigational approved
n3:halfLife
approximately 20 days (range: 11–50 days)
n3:indication
As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
n3:manufacturer
n20:271B460B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00112 n9:DB00112
dcterms:title
Bevacizumab
adms:identifier
n12:50242-060-01 n13:DB00112 n18:PA130232992 n19:Bevacizumab
n3:mechanismOfAction
Bevacizumab contains human framework regions with antigen binding regions of a humanised murine antibody that binds to VEGF. Bevacizumab is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and is purified by a process that includes specific viral inactivation and removal steps. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel proliferation and in response retardation of metastatic tumor growth occurs.
n3:packager
n20:271B4609-363D-11E5-9242-09173F13E4C5 n20:271B460A-363D-11E5-9242-09173F13E4C5
n3:patent
n23:2286330 n23:2145985
n3:synonym
Avastin antiVEGF
n3:toxicity
Category C in pregnancy. No studies on lactating patients: recommended to discontinue the drug or discontinue lactation. No extensive studies in pediatrics. In geriatrics: increased risk of proteinuria, arterial thromboembolic events, as well as GI bleeding and sepsis among others.
n3:volumeOfDistribution
Vd: 46 mL/kg
n16:hasAHFSCode
n17:10-00-00
n7:hasConcept
n8:M0443627
foaf:page
n15:avastin.htm n25:bevacizumab-solution.html
n3:Molecular-Formula
n4:271B4614-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4613-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n21:L01XC07
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
216974-75-3
n3:category
n3:clearance
* 0.26 L/day [Male patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.21 L/day [Female patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.25 L/day [Patients with higher tumor burden who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.2 L/day [patients with tumor burdens below the median who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] Clearance varies by body weight, gender, and tumor burden. Increased clearance observed in men and in patients with higher tumor burden; however, no evidence of reduced efficacy.
n3:containedIn
n10:271B460C-363D-11E5-9242-09173F13E4C5 n10:271B460D-363D-11E5-9242-09173F13E4C5 n10:271B460E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4612-363D-11E5-9242-09173F13E4C5